Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6423 · 1 trial · 1 indication
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
| Arm | Type | Description |
|---|---|---|
| Experimental: AZD6423 | EXPERIMENTAL | Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo. |
| Placebo to match AZD6423 | PLACEBO_COMPARATOR | Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| AZD6423 | DRUG | Drug: AZD6423 Single or Multiple doses via infusion. |
| Placebo | DRUG | Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion |
Inclusion Criteria: 1. Subjects must understand the nature of the study and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any study-specific procedures. 2. All male subjects who are biologically capable of having children must agre...
AZD6423 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in Phase 1 clinical development. The completed trial evaluated the drug in healthy participants to assess its safety and tolerability.
AZD6423 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker AZN. The company sponsored the Phase 1 clinical trial of this investigational small molecule.
AZD6423 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The single Phase 1 trial has been completed, and the drug is not yet available for clinical use.
AZD6423 has one completed Phase 1 trial, identified as NCT01926366, titled 'AZD6423 SAD/MAD Study in Healthy Volunteers.' The study enrolled 175 participants in the United States and was randomized, double-blind, and placebo-controlled.
AZD6423 is not FDA approved. It is an investigational drug in Phase 1 clinical development. The completed trial in healthy volunteers was designed to evaluate safety and tolerability, but the drug has not been approved for any medical use.